Class A common stock, $0.0001 par value per share
- Symbol
- PROK
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
PROKNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On November 12, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1.…
Press release in this filing
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights →ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
PROKIDNEY CORP. · 8-K · Filed 2026-11-12
Exhibit 99.1 ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights • On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 • Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by accelerated patient recruitment in mid-2026 • Presented eight abstracts at ASN Kidney Week 2026, with new data further strengthening the mechanistic and clinical evidence supporting rilparencel; subsequently hosted a KOL event recapping key ASN findings and rilparencel’s potential role in advanced CKD and type 2 diabetes • Ended the third quarter with $142 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., November 12, 2026 - ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones. “The third quarter marked continued progress for ProKidney, with …
Open exhibit ↗